WO2002024872A2 - Manipulation de spermatozoides - Google Patents
Manipulation de spermatozoides Download PDFInfo
- Publication number
- WO2002024872A2 WO2002024872A2 PCT/GB2001/004184 GB0104184W WO0224872A2 WO 2002024872 A2 WO2002024872 A2 WO 2002024872A2 GB 0104184 W GB0104184 W GB 0104184W WO 0224872 A2 WO0224872 A2 WO 0224872A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sperm
- cell
- extract
- nucleus
- reprogramming
- Prior art date
Links
- 239000000284 extract Substances 0.000 claims abstract description 121
- 238000000034 method Methods 0.000 claims abstract description 110
- 239000000872 buffer Substances 0.000 claims abstract description 19
- 150000001768 cations Chemical class 0.000 claims abstract description 12
- 239000008191 permeabilizing agent Substances 0.000 claims abstract description 11
- 230000009466 transformation Effects 0.000 claims abstract description 11
- 239000002738 chelating agent Substances 0.000 claims abstract description 9
- 229910052751 metal Inorganic materials 0.000 claims abstract description 5
- 239000002184 metal Substances 0.000 claims abstract description 5
- 238000005406 washing Methods 0.000 claims abstract description 5
- 239000003599 detergent Substances 0.000 claims abstract description 4
- 239000011536 extraction buffer Substances 0.000 claims abstract description 4
- 210000004940 nucleus Anatomy 0.000 claims description 146
- 210000004027 cell Anatomy 0.000 claims description 78
- 239000006185 dispersion Substances 0.000 claims description 52
- 230000004927 fusion Effects 0.000 claims description 49
- 210000000287 oocyte Anatomy 0.000 claims description 49
- 230000008672 reprogramming Effects 0.000 claims description 48
- 210000000633 nuclear envelope Anatomy 0.000 claims description 47
- 238000011534 incubation Methods 0.000 claims description 46
- 210000001082 somatic cell Anatomy 0.000 claims description 36
- 210000000349 chromosome Anatomy 0.000 claims description 33
- 108010077544 Chromatin Proteins 0.000 claims description 26
- 210000003483 chromatin Anatomy 0.000 claims description 26
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 23
- 210000002257 embryonic structure Anatomy 0.000 claims description 22
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 21
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 claims description 20
- 210000001161 mammalian embryo Anatomy 0.000 claims description 18
- 241001465754 Metazoa Species 0.000 claims description 15
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 13
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims description 12
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 11
- 208000031404 Chromosome Aberrations Diseases 0.000 claims description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 210000000805 cytoplasm Anatomy 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 239000008188 pellet Substances 0.000 claims description 8
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 claims description 7
- 229920002527 Glycogen Polymers 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 7
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 claims description 7
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 claims description 7
- 229940096919 glycogen Drugs 0.000 claims description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 7
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims description 6
- 230000002559 cytogenic effect Effects 0.000 claims description 6
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 6
- 229940063673 spermidine Drugs 0.000 claims description 6
- 229940063675 spermine Drugs 0.000 claims description 6
- 238000010998 test method Methods 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 4
- 102000006835 Lamins Human genes 0.000 claims description 3
- 108010047294 Lamins Proteins 0.000 claims description 3
- 238000009396 hybridization Methods 0.000 claims description 3
- 238000011065 in-situ storage Methods 0.000 claims description 3
- 210000005053 lamin Anatomy 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- DHDHJYNTEFLIHY-UHFFFAOYSA-N 4,7-diphenyl-1,10-phenanthroline Chemical compound C1=CC=CC=C1C1=CC=NC2=C1C=CC1=C(C=3C=CC=CC=3)C=CN=C21 DHDHJYNTEFLIHY-UHFFFAOYSA-N 0.000 claims description 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 2
- 241000237074 Centris Species 0.000 claims 1
- 210000001840 diploid cell Anatomy 0.000 claims 1
- 229940095674 pellet product Drugs 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 239000000523 sample Substances 0.000 description 12
- 208000000509 infertility Diseases 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 9
- 230000036512 infertility Effects 0.000 description 9
- 231100000535 infertility Toxicity 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 208000007466 Male Infertility Diseases 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000000582 semen Anatomy 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000003744 In vitro fertilisation Methods 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000011987 methylation Effects 0.000 description 6
- 238000007069 methylation reaction Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000033616 DNA repair Effects 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000035558 fertility Effects 0.000 description 5
- 208000021267 infertility disease Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000031864 metaphase Effects 0.000 description 5
- 238000000520 microinjection Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 4
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010003883 azoospermia Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 210000000918 epididymis Anatomy 0.000 description 4
- 201000010063 epididymitis Diseases 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 210000004754 hybrid cell Anatomy 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- -1 Ca2+ or Mg2+) Chemical class 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- 101000915402 Homo sapiens Deleted in azoospermia protein 1 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010007568 Protamines Proteins 0.000 description 3
- 102000007327 Protamines Human genes 0.000 description 3
- 241000255588 Tephritidae Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 102000055460 human DAZ1 Human genes 0.000 description 3
- 210000003917 human chromosome Anatomy 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 229940070353 protamines Drugs 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- PMHUSCHKTSTQEP-UHFFFAOYSA-N (4-carbamimidoylphenyl)methanesulfonyl fluoride Chemical compound NC(=N)C1=CC=C(CS(F)(=O)=O)C=C1 PMHUSCHKTSTQEP-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 108010087765 Antipain Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000257465 Echinoidea Species 0.000 description 2
- 101000808590 Homo sapiens Probable ubiquitin carboxyl-terminal hydrolase FAF-Y Proteins 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 2
- 102100038600 Probable ubiquitin carboxyl-terminal hydrolase FAF-Y Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 210000002593 Y chromosome Anatomy 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000004671 cell-free system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000003927 comet assay Methods 0.000 description 2
- 231100000170 comet assay Toxicity 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 108010046018 leukocyte inhibitory factor Proteins 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000008634 oligospermia Diseases 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000021595 spermatogenesis Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000026817 47,XYY syndrome Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 208000036646 First trimester pregnancy Diseases 0.000 description 1
- MURGITYSBWUQTI-UHFFFAOYSA-N Fluorescin Natural products OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 241001424413 Lucia Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001575980 Mendoza Species 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 231100000182 Sperm DNA damage Toxicity 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-M [(4ar,6r,7r,7ar)-6-[6-(butanoylamino)purin-9-yl]-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl] butanoate Chemical compound C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-M 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000029803 blastocyst development Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940124566 female contraceptive agent Drugs 0.000 description 1
- 239000003037 female contraceptive agent Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000036616 oligospermia Effects 0.000 description 1
- 231100000528 oligospermia Toxicity 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 230000008789 oxidative DNA damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000001935 permeabilising effect Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000000113 radiomimetic effect Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 238000002416 scanning tunnelling spectroscopy Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000008010 sperm capacitation Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 208000011317 telomere syndrome Diseases 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 201000004822 varicocele Diseases 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 238000007879 vasectomy Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/061—Sperm cells, spermatogonia
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
Definitions
- a further advantage is that the transformed sperm nuclei, once assembled, can be stored in liquid nitrogen (-176°C) or at -70°C for up to 4-6 months.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne un procédé de perméabilisation de sperme consistant à : (a) laver un échantillon contenant du sperme dans un tampon d'extraction nucléaire de sperme (SNEB) comprenant un ou plusieurs agent(s) de chélation métallique et quasiment dépourvu(s) de détergents non ioniques et de cations divalents; (b) mettre en contact le sperme avec un ou plusieurs agent(s) de perméabilisation; et (c) éventuellement séparer la queue du sperme de sa tête. L'invention concerne également un procédé de transformation du sperme dont le procédé consiste à laisser incuber un échantillon de sperme ou des noyaux de sperme dans un ou plusieurs extrait(s) dépourvu(s) de cellule. L'invention concerne enfin des extraits et des tampons à utiliser avec ces procédés, des procédés de fabrication desdits extraits et des utilisations de noyaux de sperme transformé.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2001287897A AU2001287897A1 (en) | 2000-09-19 | 2001-09-19 | Manipulation of spermatozoa |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0022981.5 | 2000-09-19 | ||
| GB0022981A GB0022981D0 (en) | 2000-09-19 | 2000-09-19 | Manipulation of spermatozoa |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2002024872A2 true WO2002024872A2 (fr) | 2002-03-28 |
| WO2002024872A3 WO2002024872A3 (fr) | 2002-08-08 |
| WO2002024872A8 WO2002024872A8 (fr) | 2004-04-15 |
Family
ID=9899743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2001/004184 WO2002024872A2 (fr) | 2000-09-19 | 2001-09-19 | Manipulation de spermatozoides |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2001287897A1 (fr) |
| GB (1) | GB0022981D0 (fr) |
| WO (1) | WO2002024872A2 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1356277A2 (fr) * | 2000-12-22 | 2003-10-29 | Nucleotech, LLC | Procedes pour modifier le destin cellulaire |
| US7125976B2 (en) | 2003-07-01 | 2006-10-24 | Trustees Of Columbia University In The City Of New York | Method of screening for agents inhibiting chloride intracellular channels |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995021860A1 (fr) * | 1994-02-10 | 1995-08-17 | Simeg Ltd | Procedes pour faire varier la condensation de la chromatine |
| US5651992A (en) * | 1993-02-03 | 1997-07-29 | Brandeis University | In vitro activation of human fetal cells |
-
2000
- 2000-09-19 GB GB0022981A patent/GB0022981D0/en not_active Ceased
-
2001
- 2001-09-19 AU AU2001287897A patent/AU2001287897A1/en not_active Abandoned
- 2001-09-19 WO PCT/GB2001/004184 patent/WO2002024872A2/fr active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5651992A (en) * | 1993-02-03 | 1997-07-29 | Brandeis University | In vitro activation of human fetal cells |
| WO1995021860A1 (fr) * | 1994-02-10 | 1995-08-17 | Simeg Ltd | Procedes pour faire varier la condensation de la chromatine |
Non-Patent Citations (8)
| Title |
|---|
| COLLAS PHILIPPE ET AL: "Formation of the sea urchin male pronucleus in vitro: Membrane-independent chromatin decondensation and nuclear envelope-dependent nuclear swelling." MOLECULAR REPRODUCTION AND DEVELOPMENT, vol. 42, no. 1, 1995, pages 106-113, XP001034081 ISSN: 1040-452X cited in the application * |
| GORDON K ET AL: "IN-VITRO ACTIVATION OF HUMAN SERUM INDUCED BY AMPHIBIAN XENOPUS-LAEVIS EGG EXTRACT" EXPERIMENTAL CELL RESEARCH, vol. 157, no. 2, 1985, pages 409-418, XP002194533 ISSN: 0014-4827 * |
| KAWASAKI KATSUMI ET AL: "Chromatin decondensation in Drosophila embryo extracts." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 13, 1994, pages 10169-10176, XP002194536 ISSN: 0021-9258 * |
| LOHKA M J ET AL: "ROLES OF CYTOSOL AND CYTOPLASMIC PARTICLES IN NUCLEAR ENVELOPE ASSEMBLY AND SPERM PRONUCLEAR FORMATION IN CELL-FREE PREPARATIONS FROM AMPHIBIAN EGGS" JOURNAL OF CELL BIOLOGY, vol. 98, no. 4, 1984, pages 1222-1230, XP001037656 ISSN: 0021-9525 cited in the application * |
| LU PING ET AL: "Nuclear assembly of demembranated Xenopus sperm in plant cell-free extracts from Nicotiana ovules." EXPERIMENTAL CELL RESEARCH, vol. 270, no. 1, 15 October 2001 (2001-10-15), pages 96-101, XP002185219 ISSN: 0014-4827 * |
| NEUBER EVELYN ET AL: "Efficient human sperm pronucleus formation and replication in Xenopus egg extracts." BIOLOGY OF REPRODUCTION, vol. 61, no. 4, October 1999 (1999-10), pages 912-920, XP002194535 ISSN: 0006-3363 * |
| POCCIA D ET AL: "Transforming sperm nuclei into male pronuclei in vivo and in vitro." CURRENT TOPICS IN DEVELOPMENTAL BIOLOGY, vol. 34, 1996, pages 25-88, XP001038289 1996 Academic Press, Inc.;Academic Press Ltd. 1250 Sixth Ave., San Diego, California 92101, USA; 14 Belgrave Square, 24-28 Oval Road, London NW1 70X, England, UK ISBN: 0-12-153134-1 * |
| SAWYER DENNIS E ET AL: "The use of an in vitro sperm activation assay to detect chemically induced damage of human sperm nuclei." REPRODUCTIVE TOXICOLOGY, vol. 9, no. 4, 1995, pages 351-357, XP002194534 ISSN: 0890-6238 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1356277A2 (fr) * | 2000-12-22 | 2003-10-29 | Nucleotech, LLC | Procedes pour modifier le destin cellulaire |
| EP1356277A4 (fr) * | 2000-12-22 | 2005-09-28 | Nucleotech Llc | Procedes pour modifier le destin cellulaire |
| US7736895B2 (en) | 2000-12-22 | 2010-06-15 | Kyowa Hakko Kirin Co., Ltd. | Methods for altering cell fate |
| US7125976B2 (en) | 2003-07-01 | 2006-10-24 | Trustees Of Columbia University In The City Of New York | Method of screening for agents inhibiting chloride intracellular channels |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001287897A1 (en) | 2002-04-02 |
| GB0022981D0 (en) | 2000-11-01 |
| WO2002024872A3 (fr) | 2002-08-08 |
| WO2002024872A8 (fr) | 2004-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | Sex‐related differences in developmental rates of bovine embryos produced and cultured in vitro | |
| Rho et al. | Sperm and oocyte treatments to improve the formation of male and female pronuclei and subsequent development following intracytoplasmic sperm injection into bovine oocytes | |
| Galli et al. | Mammalian leukocytes contain all the genetic information necessary for the development of a new individual | |
| Farin et al. | Development of fetuses from in vitro–produced and cloned bovine embryos | |
| Mitalipov et al. | Monozygotic twinning in rhesus monkeys by manipulation of in vitro-derived embryos | |
| US20060021076A9 (en) | Prenatal screening | |
| Edwards et al. | New advances in human embryology: implications of the preimplantation diagnosis of genetic disease | |
| US6700037B2 (en) | Method of cloning porcine animals | |
| JP2002530105A (ja) | ブタ族動物のクローニングの方法 | |
| JP2002512510A (ja) | 動物のクローニング方法 | |
| Fahrudin et al. | Analysis of DNA fragmentation in bovine somatic nuclear transfer embryos using TUNEL | |
| Johnson | Human in vitro fertilisation and developmental biology: a mutually influential history | |
| JP2003533976A (ja) | 胚分割による霊長類子孫のクローン性増殖 | |
| Park et al. | Assisted reproductive techniques and genetic manipulation in the common marmoset | |
| Campbell et al. | Nuclear transfer | |
| Peura et al. | No differences in sheep somatic cell nuclear transfer outcomes using serum-starved or actively growing donor granulosa cells | |
| Kono et al. | Development of single blastomeres from four‐and eight‐cell mouse embryos fused into the enucleated half of a two‐cell embryo | |
| Yanagimachi | Problems of sperm fertility: A reproductive biologist's view | |
| Bhojwani et al. | Developmental competence of HMCTM derived bovine cloned embryos obtained from somatic cell nuclear transfer of adult fibroblasts and granulosa cells | |
| CA2389117A1 (fr) | Procedes et compositions ameliorant le potentiel de developpement d'oocytes et de zygotes | |
| Eyestone et al. | Nuclear transfer from somatic cells: applications in farm animal species | |
| CA2396210A1 (fr) | Procede de clonage d'animaux avec modifications genetiques ciblees, par transfert de noyaux cellulaires somatiques males ou femelles a culture a long terme, comprenant des modifications genetiques provoquees artificiellement, dans des cellules receveuses enuclees | |
| WO2002024872A2 (fr) | Manipulation de spermatozoides | |
| Cohen et al. | Micromanipulation in clinical management of fertility disorders | |
| TANAKA et al. | Influence of nocodazole on the development of donor blastomeres from 16-cell stage bovine embryos in nuclear transfer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| CFP | Corrected version of a pamphlet front page | ||
| CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 13/2002 DUE TO A TECHNICAL PROBLEMAT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING UNDER (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION |
|
| NENP | Non-entry into the national phase in: |
Ref country code: JP |